CorMedix Inc. (CRMD)
Automate Your Wheel Strategy on CRMD
With Tiblio's Option Bot, you can configure your own wheel strategy including CRMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRMD
- Rev/Share 1.7884
- Book/Share 3.248
- PB 3.4113
- Debt/Equity 0.002
- CurrentRatio 7.8225
- ROIC 0.2208
- MktCap 827039853.0
- FreeCF/Share 0.4477
- PFCF 27.1962
- PE 14.7116
- Debt/Assets 0.0017
- DivYield 0
- ROE 0.4273
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRMD | D. Boral Capital | Hold | Buy | -- | $14 | Oct. 20, 2025 |
| Downgrade | CRMD | D. Boral Capital | Buy | Hold | -- | -- | June 30, 2025 |
| Initiation | CRMD | H.C. Wainwright | -- | Buy | -- | $20 | June 30, 2025 |
| Initiation | CRMD | Leerink Partners | -- | Outperform | -- | $18 | March 7, 2025 |
| Initiation | CRMD | D. Boral Capital | -- | Buy | -- | $15 | Jan. 13, 2025 |
| Initiation | CRMD | Rodman & Renshaw | -- | Buy | -- | $13 | Aug. 26, 2024 |
News
Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Bet on 5 Top-Ranked Stocks With Rising P/E
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
Read More
All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Read More
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
Read More
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
Read More
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Negative
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
Read More
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
Read More
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Read More
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
Read More
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Read More
CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
CorMedix Inc. (NASDAQ:CRMD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Joseph Todisco - CEO & Director Conference Call Participants Ross Cohen Presentation Ross Cohen Okay. So thank you all for joining.
Read More
CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
Read More
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Why CorMedix (CRMD) Might be Well Poised for a Surge
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
CorMedix, Inc. (NASDAQ:CRMD ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Joseph Todisco - CEO & Director Matthew T. David - Executive VP & CFO Conference Call Participants Anish Nikhanj - RBC Capital Markets, Research Division Brandon Richard Folkes - H.C.
Read More
CorMedix to Buy Melinta Therapeutics for $300 Million
Published: August 07, 2025 by: WSJ
Sentiment: Positive
The buyer said the deal adds six marketed infectious-disease products to its offerings.
Read More
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to a loss of $0.25 per share a year ago.
Read More
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for CorMedix (CRMD) points to a 65.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive?
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
CorMedix Seems Significantly Undervalued
Published: June 30, 2025 by: Seeking Alpha
Sentiment: Positive
CorMedix offers high upside potential with DefenCath, the only FDA-approved catheter lock solution for CRBSI, and a strong financial position. My DCF model shows a base-case fair value of $26.2 per share, representing 110% upside; the options market also signals bullish sentiment. Key risks include reliance on a single product and high market share uncertainty, so I keep my position size small and avoid options due to illiquidity and high premiums.
Read More
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Published: June 27, 2025 by: Benzinga
Sentiment: Negative
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday.
Read More
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
CorMedix inc. Announces Customer Implementation
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025.
Read More
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Positive
I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, drives exponential revenue and profitability, with high adoption potential. CRMD's competitive edge lies in its first-mover advantage, high efficacy, and significant penetration in the US dialysis market.
Read More
CorMedix: Exceeding Expectations
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Positive
CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst support and some recent upwardly revised price targets, reflecting confidence in continued growth.
Read More
About CorMedix Inc. (CRMD)
- IPO Date 2010-05-13
- Website https://www.cormedix.com
- Industry Biotechnology
- CEO Joseph Todisco MBA
- Employees 64